Trial Search Results

A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: General Electric

Stanford Investigator(s):


  • Drug: 68-Ga RM2
  • Drug: 68-Ga PSMA11
  • Device: Investigational software and coils in PET/MR Scan
  • Procedure: PET/MRI


Phase 1/Phase 2


Inclusion Criteria:

   - Known prostate cancer

   - Planned HIFU or HDR local therapy

   - Able to provide written consent

   - Karnofsky performance status of 50 (or Eastern Cooperative Oncology Group (ECOG)
   /World Health Organization (WHO) equivalent)

Exclusion Criteria:

   - Patients not capable of getting PET study due to weight, claustrophobia, or inability
   to lay still for the duration of the exam

   - Metallic implants (contraindicated for MRI)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Brittney Williams